Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment

BMC Med Genomics. 2023 Nov 17;16(1):295. doi: 10.1186/s12920-023-01724-3.

Abstract

Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma.

Keywords: Cancer; Epigenetics; Histone deacetylases; Non-coding genome.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Histone Deacetylase 6
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use
  • Histone Deacetylases / genetics
  • Histone Deacetylases / metabolism
  • Humans
  • MicroRNAs* / genetics
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics

Substances

  • Histone Deacetylases
  • Histone Deacetylase 6
  • Histone Deacetylase Inhibitors
  • MicroRNAs